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Abstract
Introduction: Submaximal exercise gas exchange may be a useful tool to track responses to therapy in pulmonary arterial hypertension 
(PAH) patients.
Methods: Three patients diagnosed with idiopathic PAH, on differing therapies, were included. Standard clinical tests (echocardiogra-
phy; 6 minute walk) were performed pre and 3–5 months after treatment. Gas exchange was measured during 3 minutes of step exercise 
at both time points.
Results: Gas exchange variables, end tidal CO2 (PETCO2) and the ratio of ventilation to CO2 production (VE/VCO2), during submaximal 
exercise were able to track patient responses to therapy over a 3–5 month period. Two patients demonstrated positive improvements, 
with an increased PETCO2 and decreased VE/VCO2 during light exercise, in response to an altered therapeutic regime. The third patient 
had a worsening of gas exchange (decreased PETCO2 and increased VE/VCO2) following no changes in the medical regime from the 
baseline visit.
Conclusion: Gas exchange variables measured during light submaximal exercise, such as PETCO2 and VE/VCO2, may be able to bet-
ter detect small changes in functional status following treatment and could, therefore, be a useful tool to track disease severity in PAH 
patients. Further study is required to determine the clinical usefulness of these gas exchange variables.
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Although the 6 minute walk test is simple and widely 
employed to assess submaximal exercise capacity and 
response to therapy in pulmonary arterial hyperten-
sion (PAH), it provides limited information.1 Maxi-
mal  cardiopulmonary  exercise  testing  (CPET)  can 
provide  more  comprehensive  physiologic  informa-
tion, but is less widely available, is subject to varying 
interpretation across centers, and may be inconve-
nient for patients to perform. Submaximal exercise 
gas exchange measurement, using simplified technol-
ogy (ie, ‘plug and play’ systems),2 may be a simple 
alternative to formal CPET that could provide infor-
mation beyond that available from a 6 minute walk.
Methods
Three patients diagnosed with idiopathic pulmonary 
arterial  hypertension  were  included  in  the  present 
report. Each patient was seen twice in the PH clinic, 
with the visits separated by approximately 3–5 months. 
As part of their assessments standard clinical tests were 
performed, which included a transthoracic echo and 
6 minute walk test, at both visits. In addition, submax-
imal exercise step tests were performed in conjunc-
tion with clinical tests, which consisted of 2 minutes 
rest, 3 minutes exercise and 1 minute recovery. Gas 
exchange was measured throughout using a SHAPE 
gas analysis system (SHAPE Medical Systems Inc, St. 
Paul, MN). The SHAPE system is a newly designed, 
small and portable gas analysis system that is self cal-
ibrating, containing built-in automated temperature, 
barometric  pressure  and  humidity  corrections.  The 
interface is simplified and the software designed so 
that extensive understanding of the methodology and 
equipment is not required (Fig. 1).2
case Descriptions
Patient A
A 29 year old female evaluated for syncope was diag-
nosed with idiopathic PAH following right heart cath-
eterization in December 2009. The pulmonary artery 
pressure  at  catheterization  was  69/29  with  a  mean 
pulmonary  arterial  pressure  (PAPm)  of  45  mmHg, 
right  atrial  pressure  (RAP)  5  mmHg,  pulmonary 
wedge  pressure  (PCW)  5  mmHg,  cardiac  output 
(Q) 4.0 L/min, cardiac index (QI) 2.52 L/min/m2 and 
pulmonary vascular resistance (PVR) 10.0 Wood units. 
The patient was subsequently started on combination 
therapy, consisting of sildenafil (Revatio®) 20 mg tid 
and inhaled trepostinil sodium (TYVASO®) titrated to 
9 breaths qid, and re-assessed approximately 3 months 
later.
Patient B
A 56 year old female who was first diagnosed with 
idiopathic PAH in September 2004. It is possible 
she may have hereditary hemorrhagic telangiectasia 
based upon frequent nosebleeds but without other 
diagnostic features. Continuous prostanoids seemed 
contraindicated because of thrombocytopenia, and 
acquired Von Willebrands disease. Most recent right 
heart catheterization from June 2009 demonstrated 
a pulmonary artery pressure of 133/40 with a PAPm 
78 mmHg, RAP 11 mmHg, PCW 10 mmHg, cardiac 
output 3.5 L/min with QI 2.09 L/min/m2 and PVR 
19.6 Wood units. The patient had been on various 
therapeutic regimes but when seen in the PH clinic 
in February 2010 was functional class III on com-
bination therapy, consisting of bosentan (Tracleer) 
125 mg tid and iloprost (Ventavis) Solution for Neb-
ulization 10 ug/1 ml by inhalation 6–7 times daily, 
and had been on this medication for approximately 
2 years. The patient remained on the same therapy 
and returned for re-assessment 5 months later.
Patient C
A 56 year old male was first diagnosed with PAH in 
2005 in the context of prior splenectomy and was sub-
sequently started on sildenafil (Revatio®) 20 mg tid 
in March 2006. The patient remained on this therapy 
Figure 1. A SHAPe system which consists of a gas analyser, laptop, 
mouthpiece and pneumotach appliance and finger pulse oximeter.
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the  dose  of  sildenafil  (Revatio®)  was  increased  to 
40 mg tid because the patient still had exercise limita-
tions that impaired quality of life. Prior to the dose 
increase the patient had a right heart catheterization 
and had a pulmonary artery pressure of 78/21 with 
a PAPm 42 mmHg, RAP 8 mmHg, PCW 10 mmHg, 
Q 6.0 L/min, QI 2.7 L/min/m2 and PVR 5.3 Wood 
units.  The  patient  was  seen  back,  and  re-tested, 
approximately 4 months later.
These cases are part of an on going study inves-
tigating gas exchange in PAH patients that has been 
reviewed  and  approved  by  the  Mayo  Institutional 
Review Board. Patient consent was obtained prior to 
testing.
Results
Traditional clinical tests
Echocardiographic measurements and 6-minute walk 
distance are shown in Table 1.
Patient  A  was  free  of  recurrent  syncope  and 
was functional class III at follow up. The 6 minute 
walk increased from 357 m to 371 m after 3 months. 
Echocardiographic  estimates  of  pulmonary  artery 
pressure suggested improvement but were felt to be 
potentially unreliable due to minimal tricuspid regur-
gitation. There did appear to be improvement in right 
heart function as the tricuspid annular plane systolic 
excursion by M-mode [TAPSE] improved from 17 to 
19 mm at 3 months. Right ventricular index of myo-
cardial  performance  (RIMP)  improved  from  0.88 
to 0.54 at 3 months, while there was no significant 
change in tricuspid lateral annulus systolic velocity 
(0.12 vs 0.11 m/sec).
Patient B remained functional class II–III. The 
6-minute  walk  distance  decreased  slightly  from 
450 m to 436 m. Estimates of right   ventricular pres-
sure by echocardiography were felt to be potentially 
spuriously  low  due  to  trivial    tricuspid  regurgita-
tion but was estimated at 65 and then 69 mmHg. 
  Echocardiographic assessments of right   ventricular 
function  were  equivocal,  with    tricuspid  lateral 
  annulus   systolic velocity changing from 0.11 m/sec to 
0.08 m/sec, RIMP 0.55 to 0.50, and TAPSE 10 mm to 
12 mm. N terminal BNP decreased from 792 pg/ml 
to 547 pg/ml.
Patient C symptomatically felt improved but had 
very little change in RVSP or lateral annulus sys-
tolic velocity, which was within the normal range at 
baseline and follow up. There was however a large 
change  in  TAPSE,  which  increased  from  21  to  a 
supranormal value of 31 mm following 4 months of 
increased sildenafil treatment. Six-minute walk dis-
tance was decreased by ∼60 metres however despite 
this decrease the patient still achieved over 100% of 
age predicted distance (595 m). NBNP level was not 
available at the baseline assessment but was 100 pg/ml 
at time of followup, compatible with preserved right 
ventricular function.
submaximal exercise Gas exchange
Patient A had an improved end-tidal CO2 (PETCO2) 
and  breathing  efficiency  (VE/VCO2  slope/ratio),  in 
accordance with improved heart function and walk 
distance, after 3-months treatment (Fig. 2). End-tidal 
CO2 was higher at rest and throughout exercise fol-
lowing  treatment  (Fig.  2A). A  similar  pattern  was 
evident for breathing efficiency where the VE/VCO2 
Table 1. Routine clinical measures used to assess pulmonary hypertension severity.
patient A patient B patient c
pre post pre post pre post
Echocardiography 
RVSP (mmHg) 
TAPSe (mm) 
Lateral annulus systolic  
velocity (m/sec) 
Cardiac index (l/min/m2)
 
49 
17 
0.12 
 
2.46
 
43 
19 
0.11 
 
2.66
 
65 
na 
0.11 
 
3.04
 
69 
12 
0.08 
 
3
 
66 
21 
0.14 
 
2.48
 
68 
31 
0.14 
 
3.15
6 minute walk 
Distance (m) 
% predicted
 
356 
50
 
370 
52
 
449.9 
87
 
436.2 
84
 
660.3 
116
 
594.8 
104
Abbreviations: RVSP, estimated right ventricle systolic pressure; TAPSE, tricuspid annular plane systolic excursion by M-mode.
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(Fig. 2B). In addition, the VE/VCO2 slope decreased 
favorably from 49, at baseline, to 43 (Fig. 2C).
Patient B had a reduced PETCO2 and breathing 
efficiency at the time of 5 month follow up.   End-tidal 
CO2 was lower at rest and during exercise (Fig. 3A) 
and  VE/VCO2  ratio  higher  at  all  points.  VE/VCO2 
slope was therefore elevated from 37 at baseline to 
45 (Fig. 3C).
Patient C demonstrated an improved PETCO2 and 
breathing efficiency during exercise. This was despite 
an actual decrease in walk distance which may reflect 
the nonspecific nature of moderate changes in walk 
distance within this well preserved range. End tidal 
CO2  was  similar  at  rest  between  the  two  condi-
tions but differed during exercise (Fig. 4A). Whilst 
PETCO2 remained constant at ∼28 mmHg during exer-
cise at baseline, after 4 months of treatment PETCO2 
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Figure 2. Patient A: Gas exchange variables at rest and during exercise 
at baseline (circle) and 3-months following treatment (square). Data is 
presented for PeTCo2 (A), Ve/VCo2 ratio (B) and Ve/VCo2 slope (c).
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Figure 3. Patient B: Gas exchange variables at rest and during exercise 
at baseline (circle) and 5-months following treatment (square). Data is 
presented for PeTCo2 (A), Ve/VCo2 ratio (B) and Ve/VCo2 slope (c).
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rest and throughout exercise (Fig. 4B) after treatment, 
as was VE/VCO2 slope (Fig. 4C), which decreased 
from 39 to 30.
Discussion
Multiple parameters are currently utilized in an effort 
to track progress of patients with pulmonary arterial 
hypertension, and each of them has their strengths 
and weaknesses. Following a major shift in thera-
peutic approach such as occurred in patient A, we 
saw  substantial  improvement  in  multiple  param-
eters  including  gas  exchange  variables.  Patient  B, 
with no fundamental change in treatment plan, had 
multiple parameters that were persistently abnormal 
but without consistent or major changes in direction. 
  Worsening of submaximal gas exchange variables, 
PETCO2 and VE/VCO2, was of concern but the sig-
nificance of such changes needs to be further eluci-
dated by serial follow up. Patient C was in a category 
of quite well preserved 6 minute walk distance and 
RV function where sensitivity of such methods for 
improvement in condition is limited. In fact he had 
little change in his right heart function/pressure by 
echo estimates aside from the increase in TAPSE, and 
a decrease in 6 minute walk distance. Gas exchange 
variables suggested there was an improved function 
following  4  months  of  therapy  and  appeared  con-
sistent with his impression of clinical improvement. 
It is possible that gas exchange variables, such as 
VE/VCO2,  are  more  sensitive  measures  than  other 
clinical measures and are able to better detect smaller 
changes earlier following treatment. Gas exchange 
data during submaximal exercise could, therefore, be 
a useful tool to track disease severity in PAH patients. 
Reduced pulmonary perfusion and V/Q (ventilatory/
perfusion) mismatch is thought to be the most likely 
cause of alterations in breathing efficiency and end-
tidal CO2 levels in PAH.
Traditional  clinical  measures  used  to  determine 
PAH severity and track patient responses to treatment 
are expensive, time consuming and require technical 
expertise (echocardiography) or lack sensitivity and 
ignore important aspects of disease (6 minute walk 
test).1 There is currently a need for more sophisti-
cated endpoints that can be simply and inexpensively 
obtained. Recently it has been suggested that measur-
ing gas exchange during exercise may be the answer, 
considering that one of the main symptoms of PAH is 
dyspnea. Submaximal CPET may be a more meaning-
ful and specific endpoint measure that allows for the 
measurement of key variables (ie, physiological dead 
space, breathing efficiency and end-tidal CO2) that 
are likely to be affected by PAH. Recent research has 
described characteristic gas exchange abnormalities in 
PAH patients, including a high VE/VCO2 slope/ratio,3 
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Figure 4. Patient C: Gas exchange variables at rest and during exercise 
at baseline (circle) and 4-months following treatment (square). Data is 
presented for PeTCo2 (A), Ve/VCo2 ratio (B) and Ve/VCo2 slope (c).
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a  low  resting  PETCO2  and  decreased  PETCO2  dur-
ing exercise.4 It has been suggested that these gas 
exchange  variables  track  physiological  changes  in 
response to therapy.5 There is potential for develop-
ing algorithms, using multiple gas exchange variables 
(ie, VE/VCO2, PETCO2 and other parameters), that may 
allow a more sophisticated and sensitive, yet simple, 
way  to  track  disease  status.  More  work  is  clearly 
required in this area to determine which parameters 
should be used and also to standardize testing so that 
there is uniformity in clinical practice.
conclusion
These cases demonstrate the potential utility of mea-
suring  submaximal  exercise  gas  exchange  to  track 
responses to therapies in PAH patients. This will need 
to be evaluated and validated in a study of multiple PAH 
patients before its potential role in a clinical setting and 
as an endpoint measure can be fully understood.
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CPET, cardiopulmonary exercise testings; PAH, pul-
monary arterial hypertension; PAPm, mean pulmonary 
artery  pressure;  PCW,  pulmonary  wedge  pressure; 
PETCO2,  end  tidal  CO2;  PVR,  pulmonary  vascular 
resistance; Q, cardiac output; QI, cardiac index; RAP, 
right  atrial  pressure;  RVSP,  right  ventricle  systolic 
pressure;  TAPSE,  tricuspid  annular  plane  systolic 
excursion by M-mode echocardiography; VE/VCO2, 
ratio of minute ventilation to expired carbon dioxide 
(a measure of breathing efficiency); V/Q, ventilation/
perfusion.
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